The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 12694187 |
9 |
Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors. |
Uppsala University |
| 15837308 |
19 |
Oximinoarylsulfonamides as potent HIV protease inhibitors. |
Abbott Laboratories |
| 8709110 |
27 |
Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design. |
Agouron Pharmaceuticals |
| 8568831 |
42 |
Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands. |
Eli Lilly |
| 8360874 |
19 |
Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. |
Merck Research Laboratories |
| 16298527 |
10 |
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains. |
University of Pennsylvania |
| 16220977 |
9 |
Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization. |
Philipps-Universitat Marburg |
| 9871711 |
22 |
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors. |
Dupont Pharmaceuticals |
| 8667359 |
36 |
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors. |
Dupont Pharmaceuticals |
| 9154969 |
20 |
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis. |
Dupont Pharmaceuticals |
| 15013001 |
10 |
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. |
Glaxosmithkline |
| 15533054 |
24 |
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. |
Glaxosmithkline |
| 15653343 |
20 |
Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'. |
Uppsala University |
| 9629473 |
34 |
Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site. |
Sankyo |
| 8879560 |
22 |
Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline. |
Sankyo |
| 10530956 |
45 |
Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site. |
Sankyo |
| 7724556 |
15 |
Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. |
Agouron Pharmaceuticals |
| 8709109 |
18 |
Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. |
Agouron Pharmaceuticals |
| 8894098 |
20 |
Discovery and optimization of nonpeptide HIV-1 protease inhibitors. |
Parke-Davis Pharmaceutical Research |
| 10465549 |
21 |
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety. |
Parke-Davis Pharmaceutical Research |
| 9371233 |
24 |
Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity. |
Parke-Davis Pharmaceutical Research |
| 7699705 |
19 |
Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding. |
Parke-Davis Pharmaceutical Research |
| 10658583 |
50 |
Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor. |
Parke-Davis Pharmaceutical Research |
| 7658450 |
20 |
Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. |
Upjohn |
| 9371244 |
59 |
4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. |
Parke-Davis Pharmaceutical Research |
| 9836627 |
9 |
Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities. |
Dupont Pharmaceuticals |
| 9089336 |
77 |
Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones. |
Upjohn |
| 9216835 |
30 |
Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. |
Boehringer Ingelheim (Canada) |
| 8642565 |
36 |
Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability. |
Sandoz Research Institute |
| 8691434 |
25 |
Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors. |
Upjohn |
| 9083477 |
11 |
Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. |
Uppsala University |
| 1588552 |
30 |
HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity. |
Merck Research Laboratories |
| 9719600 |
21 |
Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. |
Upjohn |
| 8064795 |
29 |
A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. |
Parke-Davis Pharmaceutical Research |
| 7932531 |
55 |
Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity. |
Sandoz Forschungsinstitut Ges.M.B.H. |
| 8021916 |
11 |
Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR. |
Bristol-Myers Squibb |
| 8057276 |
11 |
Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease. |
Agouron Pharmaceuticals |
| 8295206 |
6 |
Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport. |
University of Pennsylvania |
| 1588551 |
21 |
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. |
Merck Research Laboratories |
| 2002466 |
13 |
Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. |
Merck Sharp and Dohme Research Laboratories |
| | 50 |
Potent, orally bioavailable HIV-1 protease inhibitors containing noncoded D-amino acids |
Eli Lilly |
| 8494379 |
4 |
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. |
National Cancer Institute-Bethesda |
| 7783120 |
12 |
Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors. |
Upjohn |
| 7932546 |
5 |
Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. |
Upjohn |
| 8544171 |
5 |
Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. |
Upjohn |
| 8171040 |
10 |
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. |
Merck Research Laboratories |
| 8765512 |
25 |
Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase. |
Sandoz Research Institute |
| 2002465 |
14 |
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. |
Merck Research Laboratories |
| 10737742 |
23 |
2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors. |
Boehringer Ingelheim Pharmaceuticals |
| 10346931 |
18 |
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. |
Japan Energy |
| 11585445 |
10 |
Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents. |
Stockholm University |
| 8642558 |
30 |
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity. |
Bristol-Myers Squibb |
| 8230099 |
29 |
Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere. |
Glaxo Group Research |
| 8230098 |
46 |
A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships. |
Glaxo Group Research |
| 11585446 |
6 |
Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal. |
Stockholm University |
| 8765511 |
14 |
Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. |
University of Illinois At Chicago |
| 8893827 |
17 |
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. |
Upjohn |
| 8164260 |
23 |
The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors. |
Merck Research Laboratories |
| 8423599 |
26 |
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. |
Monsanto Corporate Research |
| 8423600 |
13 |
3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. |
Merck Research Laboratories |
| 8464047 |
14 |
Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. |
Merck Research Laboratories |
| 11543677 |
20 |
Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution. |
Linkoping University |
| 11170625 |
25 |
Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. |
Uppsala University |
| | 35 |
SYNTHESIS AND PHARMACOKINETICS OF POTENT CARBAMATE HIV-1 PROTEASE INHIBITORS CONTAINING NOVEL HIGH AFFINITY HYDROXYETHYLAMINE ISOSTERES |
Eli Lilly |
| | 35 |
Cycloalkylpiperazines as HIV-1 Protease Inhibitors: Enhanced Oral Absorption |
Merck Research Laboratories |
| 8759643 |
17 |
Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. |
Ciba-Geigy |
| | 4 |
INFLUENCE OF STEREOCHEMISTRY ON ACTIVITY AND BINDING MODES FOR C(2) SYMMETRY-BASED DIOL INHIBITORS OF HIV-1 PROTEASE. |
Nci-Fcrdc |
| 2200122 |
1 |
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. |
Abbott Laboratories |
| 8558507 |
7 |
A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. |
Abbott Laboratories |
Search and Browse
